Freya Meds Review: Following the Care Path From Assessment to Home Delivery

01Start by identifying who is responsible for care

Freya’s homepage describes a fully online, medically guided weight-loss program connecting patients with licensed doctors who may prescribe semaglutide or tirzepatide. Its legal structure is more specific: Freya provides administrative and technology management services to independent, state-licensed professional corporations and their clinicians. The terms say Freya itself does not practice medicine, give medical advice, diagnose or treat patients, or employ or contract with professionals to deliver clinical services.

That distinction determines where clinical responsibility sits. Under the terms, the patient-provider relationship is solely with the independent licensed professional practicing through an affiliated entity. The consulted documents do not name those professional corporations, the clinician who would handle an individual case or the dispensing pharmacies. Our guide to the clinician-platform distinction explains why identifying those separate parties is useful before enrolling.

Even the business naming deserves clarification: the terms’ heading uses FREYA MEDS INC., while the operative ownership language names FREYA MEDS International Inc. and affiliates. The documentation does not resolve those names or their relationship to the Freya GLP-1 Outcomes Platform name. This is not proof of a care problem, but patients should know which company processes payment, which entity maintains the clinical relationship and whom to contact when responsibilities overlap.

02Assessment comes before a prescribing decision

Freya describes its starting assessment as confidential, covering health, goals and lifestyle, with no commitment required. The homepage says a licensed healthcare provider reviews health history, current medications, weight-loss goals and the overall medical profile. It explicitly says not everyone qualifies. The terms set an age floor of 18. Together, these statements describe screening for possible treatment—not an entitlement to a prescription after completing a questionnaire or selecting a plan.

The semaglutide page addresses adults who have struggled to lose weight through diet and exercise and says the treatment works best for people with a BMI of 27 or above. That marketing description is not a complete eligibility policy. Freya’s individualized clinician review remains the documented decision point. The pages do not establish a mandatory laboratory panel, explain whether testing is required in particular circumstances or settle whether any associated laboratory charges are included.

Freya advertises same-day review and prescription confirmation by a U.S.-licensed doctor after a preferred option is selected. That is a claimed review timetable, not a guaranteed prescription or delivery date. The consulted material also does not establish whether every assessment requires video, telephone or asynchronous communication. Before paying, ask what encounter will occur, who conducts it and what happens to the payment if treatment is declined. Preparing a medication list and questions can make that encounter more useful.

03Check location and payment before moving through checkout

Freya’s homepage says it has more than 450,000 patients across all 50 U.S. states. That is a provider-reported scale claim, not confirmation of current service availability in every state. The terms explicitly exclude Alabama, Mississippi and West Virginia and say residents there cannot complete checkout for services. They also limit use to people located in the United States. Those specific restrictions matter more for enrollment planning than the broad nationwide marketing language.

The payment pathway is direct-pay. Freya’s terms say neither the company nor its affiliated professional entities accept commercial insurance, participate in commercial networks or enroll in Medicare or Medicaid. This describes the service’s payment model; it should not be expanded into an undocumented claim that anyone with government coverage is categorically ineligible. Patients should establish their expected out-of-pocket obligations directly rather than assuming an advertised medication program will bill their health plan.

The terms assign users responsibility for charges associated with professional, laboratory and pharmacy services, with payments handled by third-party processors. Meanwhile, the homepage says the price usually includes medication, syringes, shipping, consultations and support. “Usually” leaves room for exceptions. Ask for the complete charge breakdown, including whether any required testing or outside-pharmacy fulfillment adds costs. That question is particularly important when a bundled marketing description sits alongside broader legal responsibility for fees.

04The payment schedule and care schedule need to match

Freya publishes two different price presentations. The homepage lists semaglutide starting as low as $150 per month and tirzepatide starting as low as $249 per month, without explaining the qualifying conditions in that passage. Treatment pages instead list semaglutide at $250 per month with quarterly billing and delivery, or $297 for monthly plans; tirzepatide is $332 per month with quarterly billing and delivery, or $390 for monthly plans. These are alternatives, not evidence that quarterly payment is mandatory.

The pages do not reconcile those figures or identify the exact formulation, route and presentation attached to each price. A homepage promotion advertises up to $272 off three-month plans at checkout, ending October 31, but gives no year. Its validity cannot be assumed. Freya also says payment covers the full monthly treatment plan rather than a particular vial, with the price staying the same regardless of the clinician’s dose determination. That does not independently establish a permanent price guarantee.

Freya advertises no membership fees, no lock-in and month-to-month care, while its treatment pages offer quarterly billing and delivery and say “Cancel anytime.” The documents do not establish renewal mechanics, cancellation steps, notice deadlines, refunds or the treatment of unused quarterly prepayments. Quarterly scheduling alone establishes neither a minimum commitment nor a specific supply quantity. Before choosing a billing interval, obtain written terms explaining the first charge, subsequent charges and what cancellation changes—and does not return.

05A prescription still needs an identifiable product and pharmacy

Freya’s terms contemplate compounded medication when an independent clinician considers it appropriate. They explain that compounded products are prepared by licensed pharmacies for individual patients and are not FDA reviewed or approved for safety, efficacy or manufacturing quality. The consulted pages do not establish the exact formulation, presentation, administration route or compounded status of every product actually dispensed. References to syringes, vials or familiar ingredient names cannot substitute for a written product identification.

The pharmacy choice is conditional. Patients may select a partner in the Freya Meds Pharmacy Network; they may also choose their own pharmacy when prompted during use of the service. This is not an unrestricted promise that every plan can be fulfilled anywhere at the advertised bundled price. The pharmacy-handoff guide offers a useful framework: confirm the dispenser, the prescribed preparation, the instructions and responsibility for resolving fulfillment questions before shipment.

FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Compounded preparations are not FDA approved, but nonapproval alone does not establish clinical inequivalence or judge this provider. Freya and its affiliated entities also disclaim guarantees concerning compounded medication’s safety, efficacy, purity and quality. Neither ingredient comparisons nor branded-drug research can establish the performance of an unidentified preparation supplied through this program.

06Separate approval, shipping and arrival

Freya advertises free, discreet shipping and monthly medication delivery on its homepage. Its treatment pages advertise “Fast 3 Day Shipping,” while the quarterly options explicitly pair quarterly billing with quarterly delivery. The three-day phrase does not explain when the clock starts or distinguish dispatch, transit and arrival. It should not be combined with same-day clinical review to manufacture a payment-to-doorstep deadline. The consulted documents do not provide that complete timeline.

The tirzepatide page describes medication delivered properly stored and ready to use, but the available documentation does not explain packaging, refrigeration procedures, carrier arrangements, tracking, replacement policies or delivery-problem escalation. Another concrete detail appears in the terms: medication fulfilled through Freya’s pharmacy network will not arrive in child-resistant packaging, and patients must keep it out of children’s reach. That is a practical household-storage consideration, not merely a contractual technicality.

For an injectable GLP-1 medicine that arrives warm or inadequately refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. Our guide to warm injectable deliveries explains that advice without assuming what any particular shipment contains. Before ordering, identify the contact responsible for a temperature concern and ask how an interrupted delivery affects replacement and the care schedule. Freya’s general storage assurance does not answer those operational questions.

07Follow-up is a substantial promise, but access needs definition

Freya’s follow-up offering is broader than medication shipment alone. The semaglutide page advertises the same doctor from start to finish, weekly check-ins and adjustments. Other pages describe practitioner messaging, a direct line to the doctor familiar with the case, and unlimited clinician and care-team access. These are provider-described service commitments, not independently verified performance. The documentation does not specify guaranteed reply times, check-in format or arrangements when the assigned professional is unavailable.

The supporting resources include nutrition plans, meal guidance, lifestyle coaching, habit-building tools and dashboard-based progress tracking. The treatment offering also lists unlimited doctor consultations, monthly group calls and a one-on-one consultation with Freya’s dietitian; the homepage describes monthly expert sessions with questions and answers. Those components could make the service more structured than a prescription-only transaction, but the documents do not establish the duration, scheduling availability or additional-session entitlement for the individual nutrition consultation.

Freya tells patients to contact their practitioner directly if something does not feel right, with the clinician responsible for changing the approach based on the response. NIDDK likewise describes follow-up as attention to tolerance and response, not simply continued payment. The practical question is how Freya makes that contact work between scheduled check-ins. Our guide to ongoing GLP-1 support helps separate access claims from response expectations, while leaving treatment decisions to the treating clinician.

08Keep administrative contacts separate from clinical escalation

Freya’s privacy policy lists contact@freyameds.com, an address at 30 N Gould St Ste R, Sheridan, Wyoming 82801, and hours of 8 a.m. to 8 p.m. Eastern, Monday through Sunday. Those published hours do not establish that a prescribing clinician is continuously available throughout them. Nor do the consulted pages confirm Spanish-language care, interpretation, disability-access arrangements or guaranteed team response times. Patients needing a particular communication format should establish it before relying on the service.

The terms provide a separate records-transfer route: email doctor@freyameds.com with consent and the receiving healthcare provider’s name, address and telephone number to request transmission of the telehealth record. The privacy policy also allows requests for data access, correction or deletion and limits on certain processing, subject to applicable law, through the general contact email. These are useful continuity tools, although the documents do not specify completion times for individual requests.

Freya expressly excludes emergency care. Its terms direct people experiencing a medical emergency to call 911 and seek immediate treatment, rather than depend on platform messaging. For ordinary continuity needs, the unresolved issue is who coordinates records, pharmacy questions and ongoing care if a plan ends or a clinician changes. Establishing those responsibilities in advance is more useful than assuming that unlimited access, cancellation flexibility and advertised continuity automatically cover every transition.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Freya / Freya Meds — official website ↗
4. Freya / Freya Meds — how it works ↗
5. Freya / Freya Meds — privacy policy ↗
6. Freya / Freya Meds — terms and conditions ↗
7. Freya / Freya Meds — semaglutide ↗
8. Freya / Freya Meds — tirzepatide ↗

Continue reading

• The GLP-1 Care Journey: Who Handles Intake, Prescribing, Delivery and Follow-Up?
• Who Provides Your Care When You Use a Telehealth Platform?
• From Prescription to Dispensing: Questions for the GLP-1 Pharmacy Handoff
• When Injectable Medicine Arrives Warm: Reading the FDA Advice
• What Ongoing GLP-1 Support Actually Means